NO160439B - Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte imidazol-derivater. - Google Patents
Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte imidazol-derivater. Download PDFInfo
- Publication number
- NO160439B NO160439B NO822183A NO822183A NO160439B NO 160439 B NO160439 B NO 160439B NO 822183 A NO822183 A NO 822183A NO 822183 A NO822183 A NO 822183A NO 160439 B NO160439 B NO 160439B
- Authority
- NO
- Norway
- Prior art keywords
- copolymer
- solution
- compounds
- preparation
- olefin
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 1
- 229940079865 intestinal antiinfectives imidazole derivative Drugs 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
- 229920001577 copolymer Polymers 0.000 claims description 30
- 239000000243 solution Substances 0.000 claims description 24
- 229910052783 alkali metal Inorganic materials 0.000 claims description 11
- -1 alkali metal salt Chemical class 0.000 claims description 9
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 claims description 6
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 claims description 6
- 229920005989 resin Polymers 0.000 claims description 6
- 239000011347 resin Substances 0.000 claims description 6
- 239000004711 α-olefin Substances 0.000 claims description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 5
- 239000003637 basic solution Substances 0.000 claims description 5
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- 239000000908 ammonium hydroxide Substances 0.000 claims description 4
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 3
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims description 3
- 229910001854 alkali hydroxide Inorganic materials 0.000 claims description 2
- 150000001336 alkenes Chemical class 0.000 claims description 2
- 150000001450 anions Chemical class 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- 239000011248 coating agent Substances 0.000 claims description 2
- 238000000576 coating method Methods 0.000 claims description 2
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims description 2
- 159000000000 sodium salts Chemical class 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 abstract description 5
- 150000001875 compounds Chemical class 0.000 abstract 5
- 241000124008 Mammalia Species 0.000 abstract 1
- 230000000843 anti-fungal effect Effects 0.000 abstract 1
- 230000001857 anti-mycotic effect Effects 0.000 abstract 1
- 230000002785 anti-thrombosis Effects 0.000 abstract 1
- 239000003146 anticoagulant agent Substances 0.000 abstract 1
- 239000002220 antihypertensive agent Substances 0.000 abstract 1
- 229940030600 antihypertensive agent Drugs 0.000 abstract 1
- 239000002543 antimycotic Substances 0.000 abstract 1
- 230000001882 diuretic effect Effects 0.000 abstract 1
- 231100000252 nontoxic Toxicity 0.000 abstract 1
- 230000003000 nontoxic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 7
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 6
- 239000007787 solid Substances 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 235000011114 ammonium hydroxide Nutrition 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 239000012736 aqueous medium Substances 0.000 description 3
- 239000004289 sodium hydrogen sulphite Substances 0.000 description 3
- 239000008096 xylene Substances 0.000 description 3
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- LSXWFXONGKSEMY-UHFFFAOYSA-N di-tert-butyl peroxide Chemical compound CC(C)(C)OOC(C)(C)C LSXWFXONGKSEMY-UHFFFAOYSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 229910000881 Cu alloy Inorganic materials 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- RSWGJHLUYNHPMX-ONCXSQPRSA-N abietic acid Chemical compound C([C@@H]12)CC(C(C)C)=CC1=CC[C@@H]1[C@]2(C)CCC[C@@]1(C)C(O)=O RSWGJHLUYNHPMX-ONCXSQPRSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 229920006026 co-polymeric resin Polymers 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229910052701 rubidium Inorganic materials 0.000 description 1
- IGLNJRXAVVLDKE-UHFFFAOYSA-N rubidium atom Chemical compound [Rb] IGLNJRXAVVLDKE-UHFFFAOYSA-N 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical compound [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/63—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by introduction of halogen; by substitution of halogen atoms by other halogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/69—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by addition to carbon-to-carbon double or triple bonds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
- C07C45/68—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms
- C07C45/72—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups
- C07C45/74—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton by increase in the number of carbon atoms by reaction of compounds containing >C = O groups with the same or other compounds containing >C = O groups combined with dehydration
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
- C07C49/20—Unsaturated compounds containing keto groups bound to acyclic carbon atoms
- C07C49/213—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing six-membered aromatic rings
- C07C49/217—Unsaturated compounds containing keto groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Catalysts (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Description
Harpiksoppløsning for impregnering eller belegning av papir.
Nærværende oppfinnelse vedrører vandige, basiske oppløsninger av syntetiske harpikser med forbedrede egenskaper for behandling av papir og papirprodukter, og vedrører en forbedring av de i patent nr. 111 787 angitte harpikser.
Harpiksoppløsningene ifølge nærværende oppfinnelse består av en vandig, basisk oppløsning, fortrinnsvis av alkalihydroxyd eller ammoniumhydroxyd av en alifatisk alken-a-olefin/maleinsyreanhydrid kopolymer med et molart forhold mellom olefin og maleinsyreanhydrid på 1:1 til 1:1,9 og en gjennomsnittlig molekylvekt på 1000—10 000, og hvor a-olefinene inne-'li<p>flder 6—24 fortrinnsvis fra 14—18, car-boriatomer, som angitt i norsk patent nr. 11<*>1787 og karakteriseres ved at de inneholder fra 0,01—5 pst., basert på kopoly-merinnholdet av et alkalimetallsalt, fortrinnsvis natriumsaltet, av et anion valgt fra gruppen bestående av bisulfit og sulfit.
Den alifatiske alken-a-olefin-malein-syreanhydridkopolymer fremstilles som angitt i norsk patent nr. 111 787.
Alkalimetallbisulfitet eller alkalime-tallsulfitet kan innarbeides i kopolymer-oppløsningen etter en kjent metode, eller alkalimetallbisulfitet kan blandes med den tørrede, pulveriserte kopolymer i egnede mindre mengder før kopolymeren oppløses i det vandige medium og den tørrede blanding av kopolymeren og alkalimetallbisulfitet eller sulfitet kan tilsettes som så-dant til det vandige medium. Eventuelt kan den tørrede kopolymer og alkalimetallbisulfitet eller sulfitsaltet tilsettes se-parat til det vandige medium. Det er foretrukket først å oppløse en gitt mengde av de faste kopolymerer i et vandig, basisk medium, og derpå tilsette den mindre mengde, fortrinnsvis fra 0,1 til 5 pst. av saltet basert på vekten av polymeren til den slik oppnådde oppløste kopolymeropp-løsning.
Bisulfit- og/eller sulfitionene kan til-føres kopolymeroppløsningen i enhver hen-siktsmessig form, også i form av den fri syre eller som flytende SOg så lenge som en basisk pH opprettholdes, eller som sal-tene med andre metaller slik som lithium, rubidium, cesium etc. så lenge som meng-den av salt som anvendes ikke er tilstrekkelig til å felle kopolymeren ut fra opp-løsningen. Imidlertid er disse materialer ikke foretrukket ut fra behandlings-, til-gjengelighets- og prisbetraktninger.
Det er foretrukket å forene alkalimetallbisulfitet eller sulfitsaltet med vandige alkalimetallhydroxydoppløsninger av kopolymeren for å oppnå optimal farvestabili-tet hos det behandlede papir. Det er imidlertid blitt funnet at sammensetningen etter oppfinnelsen som er oppløst i ammo-niakk- og aminholdige baser slik som ammoniumhydroxyd har vesentlige fordeler overfor vandige ammoniakalske oppløsnin-ger av kopolymeren som ikke inneholder alkalimetallbisulfitet eller sulfitet. Blan-dingene etter oppfinnelsen oppløst på denne måte viser vesentlig motstandsevne overfor korrosjon i flytende fase når opp-løsningen oppbevares i utstyr på basis av kobberlegeringer. Dette er viktig, da ved fraværet av alkalimetallbisulfitet eller sulfitet blir den ammoniakalske blanding av kopolymeren ved henstand blå, og når far-vede oppløsninger påføres papir, misfarves papiret. Når anvendt for å forebygge mis-farvning av ammoniakalsk oppløsning av kopolymeren er vanligvis mengder så lave som ca. 0,01—1 pst. tilstrekkelige.
Den modifiserte vandige basiske kopo-lymerblandingsoppløsning oppnådd på denne måte kan påføres papir som sådan eller det kan innarbeides i den vandige oppløs-ning andre tilsetningsstoffer eller modifi-seringsmidler slik som angitt i norsk patent nr. 111 787.
Eksempel 1.
En blandet olefin-maleinsyreanhydrid kopolymer ble fremstilt som følger: Til en 22 liters flaske utstyrt med om-rører, termometer, tilbakeløpskjøler, nitro-geninnløpsrør, og et ytterligere rør ble tilsatt 4500 g (20 mol) av en kommersielt tilgjengelig CH—C18 blandet alifatisk alken-a-olefin, og ca. halvparten av 5309 g (50 mol) blandede xylener. Flasken ble spylt gjennom med nitrogen mens blandingen ble oppvarmet til ca. 140°C i løpet av 1 time. Derpå ble halvparten av 131,6 g (0,9 mol) di-iert-butylperoxyd tilsatt flasken og tilsetningen av en oppløsning av maleinsyreanhydrid og den annen halvpart av di-tert-butylperoxydet oppløst i den annen halvpart av xylenet ble tilsatt gjennom ekstrarøret i løpet av ca. 60 minutter mens temperaturen ble holdt ved 140—145°C. rert-butanoldestillasjon ble iakttatt etter ca. 45 minutters tilsetning. Blandingen ble holdt ved 136—140°C i 2
timer og derpå ble xylen drevet fra reak-sjonsblandingen i løpet av 133 minutter ved temperaturer fra 138°C opp til 170°C. Trykket ble senket til et sluttrykk på 40 mm etterhvert som temperaturen øket. Totalt destillat inklusive fert-butanol var 5530 g. Den viskøse gule harpikspolymer som ble tilbake som residuum veide 7015 g og ble helt i lagringsbeholdere. Ved av-kjøling størknet den til et gulfarvet sprøtt glass. Den ble pulverisert tilstrekkelig til å passere gjennom en 20 maskers sikt. Kopolymeren hadde en spesifik viskositet på 0,24 målt på en 4 pst. oppløsning i methyl-ethylketon ved 25°C. Den gjennomsnittlige molekylvekt var 2095.
Det flytende produkt som oppnås fra disse reaksjonsmidler før avkjøling hadde en tetthet på ca. 0,77 g/ml ved 170°C. Det hadde et smeltepunkt på ca. 110°C. Til-nærmede viskositeter for harpiksproduktet ved forskjellige temperaturer er:
Den pulveriserte faste kopolymer ble tilsatt til en omrørt, oppvarmet (50—60°C) vandig oppløsning av natriumhydroxyd som inneholder ca. 0,23 g natriumhydroxyd for hvert gram kopolymerharpiks. Opp-varmingen ble fortsatt til 80°C inntil alle harpikspartiklene var oppløst. Til deler av denne oppløsning ble det tilsatt 2 og 3 pst., basert på vekten av fast polymer, natriumbisulfit. Etter fullstendig oppløsning ble den vandige basiske oppløsning av den blandede a-olefin/maleinsyreanhydrid kopolymer som inneholder natriumbisulfitet påført papirmasse som har de egenskaper som er angitt i spalte 1 (kontroll). Virk-ningene av den kjemiske behandling er satt opp i kolonne 2, 3 og 4.
Disse data viser en vesentlig reduksjon i graden av lyshetstap ved aksellerert ovnsaldring når et papir behandles med vandige basiske oppløsninger av kopolymeren som inneholder en mindre mengde alkalimetallbisulfit.
Eksempel 2.
Til 10 grams porsjoner av en. blandet a-olefin/maleinsyreanhydrid kopolymer, fremstilt som beskrevet i eksempel 1, ble det tilsatt 40—45 g destillert vann. Under omrøring ble blandingen tilsatt ammo-niakkoppløsning ekvivalent til 0,402 ml 28 pst. ammoniumhydroxyd pr. gram kopolymer. Blandingen ble rørt om ved romtem-peratur i 10 minutter og derpå oppvarmet til 60—70°C og holdt ved denne tem-peratur i 20 minutter. pH for den vandige ammoniakalske kopolymeroppløsning var 7,7. Innholdet av fast kopolymer i oppløs-ningen ble justert til 15 pst.
Lignende oppløsninger som den foran-nevnte ble fremstilt, bortsett fra at til en slik oppløsning ble det tilsatt 0,3 vektpro-sent natriumbisulfit, basert på vekten av fast polymer.
Slike vandige ammoniakalske kopoly-
meroppløsninger, d.v.s. med og uten natriumbisulfitet, var opprinnelige klare og noe mere gulaktige enn destillert vann, og fikk henstå med stykker av neddykket kobber-tråd. Etter tre dager i kontakt med kobbe-ret hadde en vandig ammoniakalsk kopoly-meroppløsning som inneholder natriumbisulfitet ikke utviklet mere farve enn en lignende ammoniakalsk kopolymer kon-trolloppløsning som ikke var i kontakt med kobber, mens den oppløsning som ikke inneholder natriumbisulfitet hadde utviklet en avgjort blå farve.
Claims (1)
- Harpiksoppløsning for impregnering eller belegning av papir bestående av en vandig, basisk oppløsning, fortrinnsvis av alkalihydroxyd eller ammoniumhydroksyd, av en alifatisk alken-a-olefin og maleinsyreanhydrid kopolymer med et forhold mellom olefin og maleinsyreanhydrid på 1:1 til 1:1,9 og en gjennomsnittlig molekyl - vekt på 1000 til 10 000, og hvor a-olefinene inneholder fra 6 til 24, fortrinnsvis 14—18 carbonatomer, som angitt i patent 111 787, karakterisert ved at den inneholder fra 0,01 til 5 pst. basert på kopoly-merinnholdet av et alkalimetallsalt, fortrinnsvis natriumsaltet av et anion valgt fra gruppen bestående av bisulfit og sulfit.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB08121333A GB2101114B (en) | 1981-07-10 | 1981-07-10 | Substituted imidazole derivatives and their preparation and use |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO822183L NO822183L (no) | 1983-01-11 |
| NO160439B true NO160439B (no) | 1989-01-09 |
| NO160439C NO160439C (no) | 1989-04-19 |
Family
ID=10523160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO822183A NO160439C (no) | 1981-07-10 | 1982-06-28 | Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte imidazol-derivater. |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US4544664A (no) |
| EP (1) | EP0072615B1 (no) |
| JP (1) | JPS5818365A (no) |
| KR (1) | KR860001864B1 (no) |
| AT (1) | ATE17121T1 (no) |
| AU (1) | AU554125B2 (no) |
| BG (1) | BG60763B2 (no) |
| CA (1) | CA1184559A (no) |
| DD (1) | DD207713A1 (no) |
| DE (1) | DE3268111D1 (no) |
| DK (2) | DK158307C (no) |
| FI (1) | FI77858C (no) |
| GB (1) | GB2101114B (no) |
| HK (1) | HK8289A (no) |
| HU (1) | HU187773B (no) |
| IE (1) | IE53244B1 (no) |
| IL (1) | IL66271A (no) |
| NO (1) | NO160439C (no) |
| NZ (1) | NZ201176A (no) |
| SG (1) | SG65388G (no) |
| SU (1) | SU1241990A3 (no) |
| UA (1) | UA5557A1 (no) |
| ZA (1) | ZA824875B (no) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2069481B (en) * | 1980-02-13 | 1983-07-27 | Farmos Oy | Substituted imidazole derivatives |
| GB2101114B (en) * | 1981-07-10 | 1985-05-22 | Farmos Group Ltd | Substituted imidazole derivatives and their preparation and use |
| US4482723A (en) * | 1983-04-11 | 1984-11-13 | Pfizer Inc. | Process for preparation of 4-acetyl-2-substituted-imidazoles |
| US4605661A (en) * | 1984-06-18 | 1986-08-12 | Eli Lilly And Company | Aromastase inhibiting α,α-diarylimidazole-4(5)-propionitriles, α,α-diarylimidazole-4(5)-propionamides, and 4(5)-(2,2-diarylethyl)imidazoles |
| US4661508A (en) * | 1984-06-18 | 1987-04-28 | Eli Lilly And Company | Aromatase inhibiting α,α-diphenyl-4(5)imidazole-methanes or -ethanes |
| ZA854400B (en) * | 1984-06-18 | 1987-02-25 | Lilly Co Eli | 4(5)-substituted imidazoles |
| FI844786A0 (fi) * | 1984-12-04 | 1984-12-04 | Farmos Oy | Terapeutiskt utnyttjbar foerening. |
| US4600683A (en) * | 1985-04-22 | 1986-07-15 | International Business Machines Corp. | Cross-linked polyalkenyl phenol based photoresist compositions |
| GB8626287D0 (en) * | 1986-11-04 | 1986-12-03 | Ucb Sa | Substituted 1h-imidazoles |
| FI864570A0 (fi) * | 1986-11-11 | 1986-11-11 | Farmos Oy | Terapeutiskt anvaendbar foerening. |
| GB2206880B (en) | 1987-07-16 | 1991-04-24 | Farmos Oy | Optical isomers of an imidazole derivative |
| GB2210875B (en) * | 1987-10-09 | 1991-05-29 | Farmos Oy | Aromatase inhibiting 4(5)-imidazoles |
| GB2215206B (en) * | 1988-02-29 | 1991-07-03 | Farmos Oy | 4-substituted imidazole derivatives useful in perioperative care |
| GB8810067D0 (en) * | 1988-04-28 | 1988-06-02 | Ucb Sa | Substituted 1-(1h-imidazol-4-yl)alkyl-benzamides |
| GB2229719B (en) * | 1989-03-30 | 1992-04-29 | Farmos Oy | Novel aromatase inhibiting 4(5)-imidazoles |
| US5439928A (en) * | 1989-03-30 | 1995-08-08 | Orion-Yhtyma Oy | Aromatase inhibiting 4(5)-imidazoles |
| US5124157A (en) | 1989-08-18 | 1992-06-23 | Cygnus Therapeutic Systems | Method and device for administering dexmedetomidine transdermally |
| US5151526A (en) * | 1990-10-11 | 1992-09-29 | The United States Of America As Represented By The Secretary Of The Army | 4-[1-(1-naphthalenyl)ethyl]-1H-imidazole, method of making and use as an anesthetic |
| DE4042492C2 (de) * | 1990-10-18 | 1995-04-13 | Heinz W Dr Joseph | Verwendung von 4,5-Di-n-hexylimidazol zur Herstellung von fungiziden Mitteln |
| GB9111732D0 (en) * | 1991-05-31 | 1991-07-24 | Orion Yhtymae Oy | The use of certain salts of medetomidine and its optically active enantiomers to regulate the rate of transdermal administration of the drugs |
| GB2256135B (en) | 1991-05-31 | 1995-01-18 | Orion Yhtymae Oy | Transdermal administration of 4-substituted imidazoles |
| US5401851A (en) * | 1992-06-03 | 1995-03-28 | Eli Lilly And Company | Angiotensin II antagonists |
| SE9302333D0 (sv) * | 1993-07-06 | 1993-07-06 | Ab Astra | New compounds |
| GB9521680D0 (en) * | 1995-10-23 | 1996-01-03 | Orion Yhtymo Oy | New use of imidazole derivatives |
| UA64751C2 (uk) | 1997-06-25 | 2004-03-15 | Пфайзер Продактс Інк. | Спосіб лікування інсулінової толерантності речовинами, які посилюють секрецію гормону росту (варіанти) та фармацевтична композиція (варіанти) |
| AR015744A1 (es) * | 1998-04-01 | 2001-05-16 | Orion Corp | Uso de dexmedetomidina para sedacion en terapia intensiva |
| US6231594B1 (en) * | 1999-08-11 | 2001-05-15 | Radiant Medical, Inc. | Method of controlling body temperature while reducing shivering |
| ATE321552T1 (de) * | 1999-10-22 | 2006-04-15 | Takeda Pharmaceutical | 1-substituierte-phenyl-1-(1h-imidazol-4- yl)alkohole, verfahren zu deren herstellung sowie deren verwendung |
| US6582457B2 (en) * | 2001-02-15 | 2003-06-24 | Radiant Medical, Inc. | Method of controlling body temperature while reducing shivering |
| BRPI0408136A (pt) | 2003-03-07 | 2006-03-01 | Astellas Pharma Inc | derivados heterocìclicos contendo nitrogênio tendo estirila 2,6-dissubstituìda |
| JP2009524616A (ja) * | 2006-01-27 | 2009-07-02 | エフ．ホフマン−ラ ロシュ アーゲー | Ｃｎｓ疾患のための４−イミダゾール誘導体の使用 |
| EP1918282A1 (en) * | 2006-11-06 | 2008-05-07 | "Joint Stock Company Grindeks" | Method for preparing medetomidine and its salts |
| US20080146523A1 (en) * | 2006-12-18 | 2008-06-19 | Guido Galley | Imidazole derivatives |
| JP2010528034A (ja) | 2007-05-23 | 2010-08-19 | アラーガン、インコーポレイテッド | 医薬としての（（フェニル）イミダゾリル）メチルキノリニル化合物 |
| WO2008144623A1 (en) | 2007-05-23 | 2008-11-27 | Allergan, Inc. | Cyclic lactams for the treatment of glaucoma or elevated intraocular pressure |
| GB2453982B (en) * | 2007-10-24 | 2009-09-16 | Norbrook Lab Ltd | Chemical process for the preparation of Medetomidine |
| US7902247B2 (en) | 2008-01-09 | 2011-03-08 | Allergan, Inc. | Substituted-aryl-2-phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors |
| BRPI0906927A2 (pt) * | 2008-01-18 | 2015-07-21 | Allergan Inc | Compostos de substituída-aril-(imidazol)-metil)-fenila como moduladores seletivos de subtipo de receptores alfa 2b e/ou alfa 2c adrenérgicos |
| US7795263B2 (en) * | 2008-07-08 | 2010-09-14 | Wildlife Laboratories, Inc. | Pharmaceutical combination for and method of anesthetizing and immobilizing non-domesticated mammals |
| US8555875B2 (en) | 2008-12-23 | 2013-10-15 | Map Pharmaceuticals, Inc. | Inhalation devices and related methods for administration of sedative hypnotic compounds |
| CN101921234B (zh) * | 2009-06-12 | 2012-05-30 | 中国中化股份有限公司 | 一种制备美托咪啶的方法 |
| CN102753532B (zh) | 2009-12-09 | 2015-05-13 | I-技术有限公司 | 美托咪定的制备方法 |
| CN101805294B (zh) * | 2010-01-12 | 2015-06-10 | 北京华禧联合科技发展有限公司 | 盐酸右美托咪定关键中间体的制备 |
| RU2448094C1 (ru) * | 2010-12-09 | 2012-04-20 | Олег Геннадьевич Еремин | Улучшенный способ получения медетомидина или его нетоксичных фармацевтически приемлемых солей |
| RU2448095C1 (ru) * | 2010-12-09 | 2012-04-20 | Олег Геннадьевич Еремин | Способ получения детомидина или его нетоксичных фармацевтически приемлемых солей |
| KR101932206B1 (ko) | 2011-07-22 | 2018-12-24 | 캠브렉스 칼스코가 아베 | 4-치환 이미다졸의 신규 제조방법 |
| WO2013069025A1 (en) | 2011-11-11 | 2013-05-16 | Neon Laboratories Ltd. | "process for the preparation of dexmedetomidine" |
| US8242158B1 (en) | 2012-01-04 | 2012-08-14 | Hospira, Inc. | Dexmedetomidine premix formulation |
| WO2012172119A2 (en) * | 2012-05-08 | 2012-12-20 | Lonza Ltd | Method for the preparation of medetomidine |
| SG11201405611SA (en) * | 2012-05-08 | 2014-11-27 | Lonza Ag | Method for preparation of 2-(2,3-dimethylphenyl)-1-propanal |
| EP2847173B1 (en) * | 2012-05-08 | 2015-12-30 | Lonza Ltd | Method for preparation of medetomidine |
| CA2866441C (en) | 2012-06-28 | 2017-01-17 | Lonza Ltd. | Method for preparation of 2-(2,3-dimethylphenyl)-1-propanal with chloroacetone |
| JP5777841B2 (ja) | 2012-06-28 | 2015-09-09 | ロンザ・リミテッド | クロロアセトンを用いてメデトミジンを調製するための方法 |
| CN105764494A (zh) | 2013-10-07 | 2016-07-13 | 帝国制药美国公司 | 右旋美托咪啶经皮递送装置及其使用方法 |
| WO2015054059A2 (en) | 2013-10-07 | 2015-04-16 | Teikoku Pharma Usa, Inc. | Methods and compositions for treating attention deficit hyperactivity disorder, anxiety and insomnia using dexmedetomidine transdermal compositions |
| EP3054930B1 (en) | 2013-10-07 | 2020-12-02 | Teikoku Pharma USA, Inc. | Methods and compositions for transdermal delivery of a non-sedative amount of dexmedetomidine |
| CN104447562A (zh) * | 2014-03-27 | 2015-03-25 | 宁波天衡药业股份有限公司 | 一种制备盐酸右美托咪定关键中间体的新方法 |
| US20180146647A1 (en) | 2015-05-06 | 2018-05-31 | I-Tech Ab | Medetomidine for use in controlling parasitic crustaceans on fish |
| US9717796B1 (en) | 2016-04-20 | 2017-08-01 | Slypharma, Llc | Heat sterilizeable, premixed, ready to use dexmedetomidine solution packaged in a flexible plastic container |
| CN105884691B (zh) * | 2016-06-02 | 2017-08-25 | 江苏恒瑞医药股份有限公司 | 一种制备右美托咪定及其中间体的方法 |
| WO2018065288A1 (de) | 2016-10-07 | 2018-04-12 | Bayer Cropscience Aktiengesellschaft | 2-[2-phenyl-1-(sulfonylmethyl)vinyl]-imidazo[4,5-b]pyridin-derivate und verwandte verbindungen als schädlingsbekämpfungsmittel im pflanzenschutz |
| EP3568392B1 (de) | 2017-01-10 | 2021-02-24 | Bayer Aktiengesellschaft | Imidazol-derivate als schädlingsbekämpfungsmittel |
| KR20230020566A (ko) | 2017-01-10 | 2023-02-10 | 바이엘 악티엔게젤샤프트 | 해충 방제제로서의 헤테로사이클 유도체 |
| WO2018182499A1 (en) | 2017-03-29 | 2018-10-04 | I-Tech Ab | Antifouling article |
| CN108872431B (zh) * | 2018-07-09 | 2021-03-23 | 成都倍特药业股份有限公司 | 一种检测4-(1-(2,5-二甲基苯基)乙基)-1h-咪唑或/和其盐酸盐的方法 |
| US11160791B2 (en) | 2018-11-01 | 2021-11-02 | Medefil, Inc. | Dexmedetomidine injection premix formulation in ready to use (RTU) bags |
| CN111217756B (zh) * | 2019-12-11 | 2022-03-11 | 南京亿华药业有限公司 | 一种盐酸右美托咪定的制备方法 |
| CN113896684A (zh) * | 2020-07-06 | 2022-01-07 | 复旦大学 | 一种美托咪定的制备方法 |
| KR20240148807A (ko) | 2022-03-22 | 2024-10-11 | 옵쉐스트바 스 아그라니첸너이아트볫스트벤너스찌유 "빅-즈다로비예쥐보트니흐" | 메데토미딘 및 그 유도체의 제조 방법 |
| CN114671811A (zh) * | 2022-04-14 | 2022-06-28 | 南京正科医药股份有限公司 | 一种右美托咪定拆分副产物的外消旋化回收方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2946804A (en) * | 1958-12-29 | 1960-07-26 | Abbott Lab | (5-methyl-4-imidazolyl)-diphenyl carbinol salts and lower alkyl quaternaries |
| BE793407A (fr) * | 1971-12-28 | 1973-06-28 | Hoechst Ag | Imidazolyl - (2) -carbinols ayant une activite hypolipidemique et leur procede de preparation |
| AU518569B2 (en) * | 1979-08-07 | 1981-10-08 | Farmos-Yhtyma Oy | 4-benzyl- and 4-benzoyl imidazole derivatives |
| GB2069481B (en) * | 1980-02-13 | 1983-07-27 | Farmos Oy | Substituted imidazole derivatives |
| GB2092569B (en) * | 1981-02-05 | 1984-09-19 | Farmos Oy | Substituted imidazole derivatives and their preparation and use |
| GB2101114B (en) * | 1981-07-10 | 1985-05-22 | Farmos Group Ltd | Substituted imidazole derivatives and their preparation and use |
-
1981
- 1981-07-10 GB GB08121333A patent/GB2101114B/en not_active Expired
-
1982
- 1982-06-15 FI FI822140A patent/FI77858C/fi not_active IP Right Cessation
- 1982-06-28 NO NO822183A patent/NO160439C/no not_active IP Right Cessation
- 1982-06-30 IE IE1602/82A patent/IE53244B1/en not_active IP Right Cessation
- 1982-07-02 DE DE8282303496T patent/DE3268111D1/de not_active Expired
- 1982-07-02 EP EP82303496A patent/EP0072615B1/en not_active Expired
- 1982-07-02 AT AT82303496T patent/ATE17121T1/de not_active IP Right Cessation
- 1982-07-06 CA CA000406694A patent/CA1184559A/en not_active Expired
- 1982-07-06 NZ NZ201176A patent/NZ201176A/en unknown
- 1982-07-06 AU AU85628/82A patent/AU554125B2/en not_active Expired
- 1982-07-07 DK DK304382A patent/DK158307C/da not_active IP Right Cessation
- 1982-07-07 KR KR828203024A patent/KR860001864B1/ko active
- 1982-07-07 US US06/396,000 patent/US4544664A/en not_active Expired - Lifetime
- 1982-07-08 IL IL66271A patent/IL66271A/xx not_active IP Right Cessation
- 1982-07-08 ZA ZA824875A patent/ZA824875B/xx unknown
- 1982-07-08 JP JP57119692A patent/JPS5818365A/ja active Granted
- 1982-07-09 HU HU822248A patent/HU187773B/hu unknown
- 1982-07-09 UA UA3463047A patent/UA5557A1/uk unknown
- 1982-07-09 SU SU823463047A patent/SU1241990A3/ru active
- 1982-07-09 DD DD82241554A patent/DD207713A1/de not_active IP Right Cessation
-
1985
- 1985-03-19 US US06/713,654 patent/US4639464A/en not_active Expired - Lifetime
-
1986
- 1986-12-29 DK DK630486A patent/DK160610C/da not_active IP Right Cessation
-
1988
- 1988-01-11 US US07/141,810 patent/US4826864A/en not_active Expired - Lifetime
- 1988-09-30 SG SG653/88A patent/SG65388G/en unknown
-
1989
- 1989-01-26 HK HK82/89A patent/HK8289A/xx not_active IP Right Cessation
-
1994
- 1994-01-18 BG BG098382A patent/BG60763B2/bg unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO160439B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive substituerte imidazol-derivater. | |
| US4522992A (en) | Aromatic monovinyl alkenyl alphaolefin anhydride terpolymers | |
| SU1222201A3 (ru) | Состав дл проклейки бумаги | |
| US2155863A (en) | Resin compositions | |
| US2211709A (en) | Triazine-aldehyde resinous condensation products | |
| US4722990A (en) | Method for increasing the functionality of an epoxy resin | |
| EP0072099B1 (en) | Blend of epoxy resin and optionally, trimellitic anhydride containing hindered nitrogen-containing compound | |
| Wiley et al. | Sulfostyrenes. 1 Polymers and Copolymers of Potassium p-Vinylbenzenesulfonate | |
| US5731403A (en) | Low temperature manufacturing process for nylon | |
| US4113583A (en) | Method for brightening the electrodeposits of zinc from alkaline zinc electroplating baths | |
| US2519780A (en) | Herbicidal formulations | |
| NO851039L (no) | Overflateaktive midler | |
| JPH06240476A (ja) | ボイラ用薬剤 | |
| SE440922B (sv) | Galvaniskt zinkutfellningsbad for erhallande av blanka utfellningar och anvendning av detsamma for zinkutfellning | |
| US4046648A (en) | Polyamine additives in alkaline zinc electroplating | |
| US2776275A (en) | Rosin and rosin size stabilized against crystallization | |
| US3429843A (en) | Hot melt adhesives containing dimethyl alpha-methyl styrene/alpha-methyl styrene/styrene terpolymers | |
| US2877273A (en) | Improving color stability of alkyl phenols | |
| US4443358A (en) | Noncrystallizing aqueous solutions of metal salts of naphthalene sulfonic acid-formaldehyde condensation products | |
| US2362973A (en) | Noncrystallizing rosin size and method of making the same | |
| JPS60110753A (ja) | セラツク組成物 | |
| CN111362820B (zh) | 一种亚氨基二琥珀酸盐的低氨合成方法 | |
| JPS6296687A (ja) | 硫酸と酢酸の痕跡量を使用するｄｎｓのｄａｓへのベシヤン還元 | |
| US2190167A (en) | Process for production of ascorbic acid | |
| US4282345A (en) | Method of preparing resinous condensation product of an allylated alkylol phenol and an ethoxyline resin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |
Free format text: EXPIRED IN JUNE 2002 |